drugset / Trial / NCT06491563
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Phase 2
Active not recruiting
150 enrolled
Brii Biosciences Limited
Vir Biotechnology, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.
Timeline
- Start
- 2024-08-06
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRII-179 | Vaccine | — | Intramuscular |
| Subject | BRII-835 | Unknown | — | Subcutaneous |
| Subject | PEG-IFNα | Protein / enzyme biologic | — | Subcutaneous |